Inhibition of Cell Signaling by the Combi-Nitrosourea FD137 in the Androgen Independent DU145 Prostate Cancer Cell Line

Prostate

Volumn 59, Issue 1, 2004, Pages 13-21

  Qiu, Qiyu ^a   Dudouit, Fabienne ^a   Banerjee, Ranjita ^a   McNamee, James P ^b   Jean Claude, Bertrand J ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b HEALTH CANADA   (Canada)

Author keywords

BCNU; DNA damage; EGFR; Nitrosourea; Prostate cancer; Signal transduction

Indexed keywords

CARMUSTINE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; FD 110; FD 137; GEFITINIB; NITROSOUREA DERIVATIVE; QUINAZOLINE DERIVATIVE; SULFORHODAMINE B; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHOSPHORYLATION; CANCER INHIBITION; CELL CYCLE S PHASE; CELL KINETICS; CELL PROLIFERATION; COMET ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DOSE RESPONSE; DRUG ACTIVITY; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IC 50; ONCOGENE C FOS; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CARMUSTINE; CELL CYCLE; CELL LINE, TUMOR; COMET ASSAY; DNA DAMAGE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, FOS; HUMANS; MALE; NITROSOUREA COMPOUNDS; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SIGNAL TRANSDUCTION;

EID: 1642402869     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10353     Document Type: Article

References (29)

1. Sherwood ER, Van Dongen JL, Wood CG, Liao S, Kozlowski JM, Lee C. Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. Br J Cancer 1999;77:855-861.
2. Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ. ErbB kinases and NDF signaling in human prostate cancer. Oncogene 1997;15:2705-2716.
3. Visakorpi T, Kallioniemi OP, Koivula T, Harvey J, Isola J. Expression of epidermal growth factor receptor and erbB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. Mod Pathol 1992;5:643-648.
4. Morris MJ, Scher HI. Novel strategies and therapeutics for the treatment of prostate carcinoma. Cancer 2000;89:1329-1348.
5. Turner T, Chen P, Goodly LJ, Wells A. EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells. Clin Exp Metastasis 1996;14:409-418.
6. Xie H, Turner T, Wang MH, Singh RK, Siegal GP, Wells A. In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals. Clin Exp Metastasis 1999;13:407-419.
7. Ching KZ, Ramsey E, Pettigrew N, D'Cunha R, Jason M, Dodd JG. Expression of mRNA for epidermal growth factor, transforming growth factor-alpha and their receptor in human prostate tissue and cell lines. Mol Cell Biochem 1993;126:151-158.
8. Brass AL, Barnard J, Patai BL, Salvi D, Rukstalis DB. Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC-3 cell lines expressing the human androgen receptor. Cancer Res 1995;55:3197-3203.
9. Yang X, Jia X, Corvalan JRF, Wang P, Davis CG, Jakobovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999;59:1236-1243.
10. Moyer JD, Barbacci EG, Iwata K, Arnold L, Boman B, Cunningham A, DiOrio E, Doty J, Morin MJ. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997;57:4838-4848.
11. Ciardiello F, Caputo R, Bianco R, Damianco V, Pomatico G, DE Placido S, Bianco AR, Tortora G. Antitumour effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-sensitive tyrosine kinase inhibitor. Clin Cancer Res 2001;6:2053-2063.
12. 6-benzylguanine in vitro. Carcinogenesis 1993;14:1057-1060.
13. 6-(2-chloroethyl) guanine mediates the biological effects of chloroethylnitrosoureas. Environ Health Perspect 1985;62:119-126.
14. Erba E, Pepe S, Ubezio P, Lorico A, Morasca L, Mangioni C, Landoni F, D'incalci M. Mitozolomide activity on human cancer cells in vitro. Br J Cancer 1986;54:925-932.
15. Woolley PV. Clinical use of nitrosoureas in gastrointestinal cancer. In: Prestayko AW, Crooke ST, Baker LH, Carter SK, Schein PS, editors. Nitrosoureas, current status and new developments. New York: Academic Press; 1981. pp 285-291.
16. Alapetite C, Thirion P, De la Rochefediere A, Cosset JM, Moustacchi E. Analysis by alkaline comet assay of cancer patients with severe reactions to radiotherapy: Defective rejoining of radioinduced DNA strand breaks in lymphocytes of breast cancer patients. Mol Cell Endocrinol 1999;117:53-58.
17. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anti-cancer drug screening. J Natl Cancer Inst 1990;82:1107-1112.
18. McNamee JP, Mclean JR, Ferrrotto CL, Bellier PV. Comet assay: Rapid processing of multiple samples. Mutat Res 2000;466:63-69.
19. Hartley JM, Spanswick VJ, Gander M, Giacomini G, Whelan J, Souhami RL, Hartley JA. Measurement of DNA cross-linking in patients in Ifosfamide therapy using the single cell gel electrophoresis (comet) assay. Clin Cancer Res 1999;5:507-512.
20. Qiu Q, Dudouit F, Matheson SL, Brahimi F, Banerjee R, McNamee JP, Jean-Claude BJ. The Combi-targeting concept: A novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitory properties. Cancer Chemother Pharmacol 2003;51:1-10.
21. 6-alkylguanine-DNA alkyltransferase and potentiation of the cytotoxicity of chloroethylnitrosourea by 4(6)-(benzyloxy)-2,6(4)-diamino-5-(nitro or nitroso) pyrimidine derivatives and analogues. J Med Chem 1998;503:508.
22. Schein PS, Mitchell EP. Contribution of nitrosoureas to cancer treatment. Cancer Treat Rep 1986;70:31-41.
23. Kornblith PL, Smith BH, Leonard LA. Response of cultured human brain tumors to nitrosoureas: Correlation with clinical data. Cancer 1981;47:255-265.
24. Belanich M, Pastor M, Randall T, Guerra D, Kibitel J, Alas L, Li B, Citron M, Wasserman P, White A, Eyre H, Jaeckle K, Schulman S, Rector D, Prados M, Coons S, Shapiro W, Yarosh D. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumour patients treated with carmustine. Cancer Res 1996;56:783-788.
25. Waker MD, Hurwitz BS. BCNU (1,3-bis (2-chloroethyl)-1-nitrosourea; NSC-409962) in the treatment of malignant brain tumorA preliminary report. Cancer Chemother Rep 1970;54:263-271.
26. Kornblith PL, Szypko PE. Variations in response of human brain tumor to BCNU in vitro. J Neurosurg 1978;48:580-586.
27. Matheson S, McNamee J, Jean-Claude BJ. Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: A novel tumour targeting strategy. J Pharm Exp Ther 2001;296:832-840.
28. Brahimi F, Matheson S, McNamee J, Tari A, Jean-Claude BJ. Inhibition of epidermal growth factor receptor-mediated signaling by " combi-triazene" BJ2000, a new probe for the combitargeting postulates. J Pharmacol Exp Ther 2002;303:238-246.
29. Matheson SL, McNamee J, Jean-Claude BJ. Differential responses of EGFR-/-AGT-expressing cells to the "combitriazene" SMA41. Cancer Chemother Pharmacol 2003;51:11-20.